MedCity News July 25, 2024
Autobahn Therapeutics’ platform technology enables small molecules to selectively hit targets in the brain. In addition to a lead program ready for Phase 2 testing in two types of depression, the startup has a preclinical molecule with potential applications in neuroinflammatory disorders such as multiple sclerosis.
When prescription depression drugs fall short in efficacy, there’s an off-label way to help them work better: add-on doses of thyroid hormone. Clinicians have long known about this approach and some of them practice it, but the additional treatment is not problem-free. Autobahn Therapeutics’ science improves on the targeting of thyroid hormone receptors to treat depression and the startup has unveiled $100 million in financing to bring its lead drug candidate into mid-stage clinical...
Today's Sponsors
Today's Sponsor